Dr. Reddy's Laboratories Ltd. (IN:DRREDDY)
:DRREDDY
Want to see IN:DRREDDY full AI Analyst Report?
DRREDDY Stock Chart & Stats
₹1280.40
₹4.55(0.33%)
At close: 4:00 PM EST
₹1280.40
₹4.55(0.33%)
Day’s Range― - ―
52-Week Range₹1,121.20 - ₹1,377.95
Previous CloseN/A
Volume1.21M
Average Volume (3M)225.11K
Market Cap
₹1.10T
Enterprise Value₹1.17T
Total Cash (Recent Filing)₹82.59B
Total Debt (Recent Filing)₹79.34B
Price to Earnings (P/E)21.9
Beta0.57
Next Earnings
May 12, 2026EPS Estimate
11.06Next Dividend Ex-DateN/A
Dividend Yield0.63%
Share Statistics
EPS (TTM)14.52
Shares Outstanding834,617,900
10 Day Avg. Volume499,682
30 Day Avg. Volume225,111
Financial Highlights & Ratios
PEG Ratio11.98
Price to Book (P/B)2.88
Price to Sales (P/S)2.95
P/FCF Ratio50.79
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
₹1,232.50Price Target Upside-3.74% Downside
Rating ConsensusModerate Sell
Number of Analyst Covering2
EPS Forecast (FY)53.96
Revenue Forecast (FY)₹356.05B
Bulls Say, Bears Say
Bulls Say
Strong ProfitabilitySustained gross (~56%) and net (~17%) margins indicate durable operating economics versus peers, enabling the firm to fund R&D and branded initiatives. Strong margin base supports reinvestment, resilience to pricing cycles, and consistent return generation even if some product-specific pressures persist.
Conservative Balance SheetA low debt-to-equity ratio and a net cash surplus provide long-term financial flexibility to absorb regulatory or launch delays, fund capex/CDMO expansion, and pursue deals without near-term refinancing risk. This conservatism supports strategic optionality and steadier capital allocation.
Pipeline And Biologics MomentumBLA acceptance for an abatacept biosimilar and semaglutide launch filings reflect structural progress into higher‑value biologics and specialty launches. Success would diversify revenue beyond commoditized generics, expand margins, and create durable market positions in biologics and CDMO services.
Bears Say
Regulatory Uncertainty For BiologicsRegulatory setbacks (CRL, post-application actions and Form 483 observations) create material timeline and approval risk for high-margin biologics. Delays or re-inspections can push commercialization out multiple quarters, undermining projected revenue and return profiles for biologics investments.
Weak Cash ConversionSubpar cash conversion (FCF ~37% of net income) suggests earnings are not reliably translating into cash, likely from working-capital and investment drags. Over the medium term this constrains self-funded growth, raises sensitivity to capex or M&A, and increases reliance on balance-sheet buffers.
Generics Pricing And PSA Profitability PressureDeclines from key products (Lenalidomide) and low-margin PSA/unbranded generics reflect structural pricing and competition pressures. Persistent erosion in these segments reduces overall margin resilience and makes earnings more dependent on timely launches and higher‑margin biologics or branded growth.
Dr. Reddy's Laboratories Ltd. News
DRREDDY FAQ
What was Dr. Reddy's Laboratories Ltd.’s price range in the past 12 months?
Dr. Reddy's Laboratories Ltd. lowest stock price was ₹1121.20 and its highest was ₹1377.95 in the past 12 months.
What is Dr. Reddy's Laboratories Ltd.’s market cap?
Dr. Reddy's Laboratories Ltd.’s market cap is ₹1.10T.
When is Dr. Reddy's Laboratories Ltd.’s upcoming earnings report date?
Dr. Reddy's Laboratories Ltd.’s upcoming earnings report date is May 12, 2026 which is in 14 days.
How were Dr. Reddy's Laboratories Ltd.’s earnings last quarter?
Dr. Reddy's Laboratories Ltd. released its earnings results on Jan 21, 2026. The company reported ₹14.52 earnings per share for the quarter, beating the consensus estimate of ₹13.763 by ₹0.757.
Is Dr. Reddy's Laboratories Ltd. overvalued?
According to Wall Street analysts Dr. Reddy's Laboratories Ltd.’s price is currently Overvalued.
Does Dr. Reddy's Laboratories Ltd. pay dividends?
Dr. Reddy's Laboratories Ltd. pays a Annually dividend of ₹8 which represents an annual dividend yield of 0.63%. See more information on Dr. Reddy's Laboratories Ltd. dividends here
What is Dr. Reddy's Laboratories Ltd.’s EPS estimate?
Dr. Reddy's Laboratories Ltd.’s EPS estimate is 11.06.
How many shares outstanding does Dr. Reddy's Laboratories Ltd. have?
Dr. Reddy's Laboratories Ltd. has 834,617,900 shares outstanding.
What happened to Dr. Reddy's Laboratories Ltd.’s price movement after its last earnings report?
Dr. Reddy's Laboratories Ltd. reported an EPS of ₹14.52 in its last earnings report, beating expectations of ₹13.763. Following the earnings report the stock price went down -0.977%.
Which hedge fund is a major shareholder of Dr. Reddy's Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:DRREDDY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Dr. Reddy's Laboratories Ltd.
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations. This segment also engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. Its Proprietary Products segment focuses on the research and development of differentiated formulations. The Others segment engages in developing therapies in the fields of oncology and inflammation. The therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. The company has a collaboration, license, and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology targets. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
DRREDDY Stock 12 Month Forecast
Average Price Target
₹1,232.50
▼(-3.74% Downside)
Technical Analysis
Aurobindo Pharma Ltd
―
Cipla Ltd
―
Lupin Limited
―
Torrent Pharmaceuticals Ltd
―
Zydus Lifesciences Limited
―